Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

书目详细资料
Main Authors:	Craddock, C, Houlton, A, Ferguson, P, Raghavan, M, Fox, S, Dudley, L, Quek, L, Cavenagh, J, Dennis, M, McMullin, M, Pillai, S, Kelly, R, Siddique, S, Wheatley, K, Vyas, P
格式:	Conference item
出版:	American Society of Hematology 2016

相似书籍

Molecular predictors of response to azacitidine therapy: the results of the UK trials acceleration programme RAVVA study
由: Craddock, C, et al.
出版: (2017)

Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
由: Craddock, C, et al.
出版: (2017)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
由: Craddock, C, et al.
出版: (2013)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
由: Craddock, C, et al.
出版: (2013)

INDUCTION OF A CDS+ T CELL RESPONSE TO THE MAGE CANCER TESTIS ANTIGEN BY COMBINED TREATMENT WITH AZACITIDINE AND SODIUM VALPROATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
由: Goodyear, O, et al.
出版: (2010)

FACTORS DETERMINING CLINICAL RESPONSE TO 5 '-AZACITDINE AND SODIUM VALPROATE COMBINATION THERAPY IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA
由: Craddock, C, et al.
出版: (2010)

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
由: Goodyear, O, et al.
出版: (2010)

Real‐world study of the use of azacitidine in myelodysplasia in Australia
由: Anoop Enjeti, et al.
出版: (2024-06-01)

5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.
由: Craddock, C, et al.
出版: (2008)

5 ' AZACITIDINE IN COMBINATION WITH VALPROIC ACID INDUCES COMPLETE REMISSIONS IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA BUT DOES NOT ERADICATE CLONAL LEUKAEMIC STEM/PROGENITOR CELLS
由: Craddock, C, et al.
出版: (2009)

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure
由: Thomas Prébet, et al.
出版: (2013-02-01)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
由: John F. Seymour, et al.
出版: (2017-12-01)

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
由: Roland B. Walter, et al.
出版: (2014-01-01)

Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy
由: Symeonidou, V, et al.
出版: (2022)

Vorinostat-An overview
由: Aditya Kumar Bubna
出版: (2015-01-01)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.
由: Dennis, M, et al.
出版: (2013)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
由: Anjali Bhatt, et al.
出版: (2022-11-01)

Vorinostat in solid and hematologic malignancies
由: Richon Victoria M, et al.
出版: (2009-07-01)

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
由: Goodyear, O, et al.
出版: (2012)

Myelodysplasia in children with anorectal malformations
由: Karine Furtado Meyer, et al.
出版: (2006-09-01)

Chromosomal deletions in myelodysplasia.
由: Boultwood, J, et al.
出版: (1995)

Temozolomide-Induced Myelodysplasia
由: Ethan A. Natelson, et al.
出版: (2010-01-01)

Solving the mystery of myelodysplasia.
由: Jerald Radich
出版: (2008-02-01)

Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
由: Vasiliki Symeonidou, et al.
出版: (2022-08-01)

Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation.
由: Laura Bergadà, et al.
出版: (2014-01-01)

Sweet's syndrome and neutrophilic panniculitis associated with G-CSF treatment in a patient with myelodysplasia
由: Brown, V, et al.
出版: (2008)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
由: Garcia-Manero, G, et al.
出版: (2021)

Myelodysplasia Rehabilitation in Children: a Review
由: Anna M. Nekrasova, et al.
出版: (2024-10-01)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
由: Tomáš Stopka, et al.
出版: (2022-07-01)

New Insights on Iron Study in Myelodysplasia
由: Noha M. El Husseiny, et al.
出版: (2014-12-01)

Introduction to the Review Series on Myelodysplasia
由: Moshe Mittelman
出版: (2025-01-01)

Acquired spherocytosis in the setting of myelodysplasia
由: Linda Katharina Karlsson, et al.
出版: (2022-01-01)

Hemophagocytic Lymphohistiocytosis Complicating Myelodysplasia
由: Geraldine Quintero-Platt, et al.
出版: (2014-03-01)

Bone marrow immunity and myelodysplasia
由: Claude LAMBERT, et al.
出版: (2016-07-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
由: Garcia-Manero, G, et al.
出版: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
由: Garcia-Manero, G, et al.
出版: (2021)

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
由: DiNardo, CD, et al.
出版: (2021)

A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
由: Eugène D.M.B. Kroon, et al.
出版: (2020-09-01)

A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial
由: Molly Malarkey, et al.
出版: (2023-08-01)

The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.
由: Timothy B Lautz, et al.
出版: (2012-01-01)